Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01234025

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer Clinical Trial

Official title:
A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer

Clinical Trial Summary

The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01234025
Study type Interventional
Source Ionis Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 2010
Completion date December 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02814669 - Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor Phase 1
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Completed NCT00770848 - AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01599793 - Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Phase 2
Terminated NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 3
Suspended NCT04053062 - LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer Phase 1
Terminated NCT01717898 - A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01824342 - Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer Phase 3
Completed NCT00838201 - Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer Phase 3
Completed NCT04768608 - PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer Phase 1